Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.
A brain volume quantification tool that may provide early insights on neurodegenerative conditions based on magnetic resonance imaging (MRI) assessment, the artificial intelligence (AI)-enabled NeuroShield has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Currently being utilized in over 200 facilities across the world, NeuroShield offers automated brain volume assessment based upon 3D MRI scans, according to InMed.AI (InMed Prognostics), the developer of NeuroShield.
The company noted that the brain segmentation analysis provided with NeuroShield has demonstrated high accuracy rates across different clinical subgroups and magnetic strengths in a trial of 280 subjects. InMed.AI noted that NeuroShield may aid in the early detection of brain atrophy, possibly facilitating timely intervention for those at risk of dementia, Alzheimer’s disease and other neurodegenerative conditions.
“We believe that investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life,” added Latha Poonamallee, Ph.D., the founder and CEO of InMed Prognostics.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.